Targeting PRMT9 Overcomes Venetoclax Resistance in AML by Modulating Splicing and Inhibiting Translation - PubMed
2 hours ago
- #AML
- #PRMT9
- #Venetoclax resistance
- PRMT9 plays a critical role in promoting Venetoclax resistance in AML, and its inhibition re-sensitizes cells to treatment.
- Genetic ablation and pharmacological inhibition of PRMT9 synergize with Venetoclax to eradicate AML cells in preclinical models.
- PRMT9 ablation disrupts RNA splicing, leading to exon-skipping in ALG13 mRNA and downregulation of the ABCC1 transporter.
- PRMT9 inhibition suppresses protein synthesis, downregulating short-lived oncoproteins like MCL1.
- Targeting PRMT9 represents a viable strategy to overcome Venetoclax resistance in AML.